Search
Jojoba oil
go.drugbank.com/drugs/DB14252ApprovedJojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Wart Remover, Elcure AtoMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment … Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProfenamine
go.drugbank.com/drugs/DB00392ApprovedIt is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawnDotatate gallium (Ga-68) explotes its ability to detect somatostatin receptor scintigraphy and this characteristic tends to change with tumor grade which gives Ga-68 dotate a high diagnostic value. … [A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264254] By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection.
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. … IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePicosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalSodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. … The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]
Mixtures: PICOPREP 10 MG / 3,5 G /12 G ORAL ÇÖZELTI IÇIN TOZ, 2 SAŞE, CITRAFLEET 0.01 G/ 3.50 G/ 10.97 G ORAL ÇÖZELTI HAZIRLAMAK IÇIN TOZ IÇEREN SAŞE , 2 ADETProducts: MOTILAXIL-T